Warren Buffett’s crew made a splashy new bet on the housing market today, and one biotech name delivered the kind of data investors dream about. The Nasdaq quietly slipped into record territory while the rest of the tape stayed mixed. 

Stick around, today’s real story is buried a few headlines down.

Capital gains taxes can take a bigger bite out of your profits than expected.

Fortunately, some deductions may help reduce the impact — including:

Because rules and eligibility vary, many investors turn to fiduciary financial advisors for guidance.

Find an Advisor Match.

You’re looking at one software giant trying to prove AI can accelerate its growth again and one Chinese internet platform posting double-digit revenue growth. Elite Trade Club Insider readers are seeing two very different capital decisions underneath those stories: one director put nearly $1 million of fresh money into his stock, while an entity controlled by another CEO sold roughly $110 million in a single block.

Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.

A subscription gets you:

$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.

Berkshire Hathaway disclosed a fresh stake of roughly ten percent in homebuilder Lennar today, reviving chatter about whether Buffett’s team sees a housing rebound nobody else is pricing in yet.

The Nasdaq eked out another record close even as the broader market traded without much conviction.

President Trump’s comments at the UN about a coming era of superintelligence added a strange geopolitical layer to an already AI obsessed tape, while Meta’s newly unveiled Muse AI agent and Alibaba’s latest AI chip kept the artificial intelligence arms race firmly in the headlines.

Biotech had its own moment entirely, with one obesity drug developer stealing the spotlight from the macro noise.

AutoZone’s profit beat shows its expansion still has traction as revenue rose 5.6% to $6.59 billion, with new stores and stronger late-quarter demand offsetting softer comparable sales and persistent pressure on household budgets.

Thor Industries expects consumer pressure to persist after its quarterly profit topped Wall Street forecasts, while high interest rates, elevated fuel costs, and inflation continue holding back demand across the recreational-vehicle market.

Amgen’s autoimmune pipeline gained a late-stage win after dazodalibep reduced disease activity in Sjögren’s syndrome, giving the drugmaker another potential growth asset as it works to broaden revenue beyond established blockbusters.

Viking Therapeutics strengthened its obesity-drug case after monthly VK2735 dosing produced encouraging weight-loss data, potentially giving the biotech a less frequent maintenance option against treatments from Eli Lilly and Novo Nordisk.

Most eVTOL companies want to sell you a ride.

AirCar wants to sell you the aircraft.

A two-seat electric flying car targeting $99,000 — with 270+ deposit-backed reservations already on the books.

Shares are currently $1.00.

See the AirCar investment opportunity

Meta’s Muse is emerging as a potential revenue engine after rapid adoption pushed the AI assistant to the top of Apple’s App Store, strengthening expectations for advertising, commerce, and subscription opportunities.

GameStop CEO Ryan Cohen increased his commitment to the retailer after buying another 1.15 million shares for roughly $26 million, raising his direct ownership as the company continues repositioning beyond physical game sales.

Greenland Mines extended its run as the rare earth trade keeps finding new legs following this month’s US Greenland Denmark security pact.

Traders are still piling into anything tied to critical minerals on the island, and Greenland Mines remains the poster child for that story. A thin float keeps amplifying every headline. This one is not cooling off yet.

Viking Therapeutics posted durable weight loss benefit data for its obesity drug candidate today, exactly the kind of readout the market has been craving from anyone chasing GLP-1 rivals.

The results reinforced the company’s pipeline ambitions in both obesity and NASH. Analysts have been circling this name for months. Today gave them fresh reason to stay bullish.

Maze Therapeutics climbed as optimism builds around its kidney disease drug candidate, with BTIG reiterating a bullish price target on the name today.

The stock has drawn steady attention from analysts despite trading at a rich valuation relative to sales. Investors seem willing to look past that for now. Pipeline hope is doing the heavy lifting here.

New Fortress Energy tumbled as the market kept digesting the company’s previously announced one-for-fifty reverse stock split tied to its broader restructuring push.

Reverse splits often bring a rocky adjustment period as trading mechanics settle and existing holders reassess. The energy infrastructure name remains under pressure as investors weigh its balance sheet. Patience is being tested here.

AIFU gave back a big chunk of value with no distinct headline driving the move today, the kind of sharp reversal that tends to hit thinly traded, sentiment driven names hardest.

The insurance and financial services company has swung wildly in recent sessions. This looks more like a violent unwind than a reaction to any specific news. Buyer beware on this one.

Xanadu Quantum Technologies slid as a lockup expiration freed up a wave of previously restricted shares for trading, adding real supply into a stock already carrying a lofty price to sales multiple.

Quantum computing names have been volatile all year on hype alone. Today’s drop looks like simple math catching up with sentiment. Supply matters even in the hottest trades.

Bank of America once called CBDCs an “inevitable evolution” of electronic money.

The U.S. has since taken a very different path — but the global shift toward digital money is still raising questions about privacy, control, and financial independence.

That’s why thousands of investors are exploring assets outside the traditional banking system.

See the strategy Tan Gera is using to pursue more financial independence

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.